Dementia: The Epidemic of Our Time

Video

If we don't find a cure or adequate treatments, the number of individuals impacted by dementia could skyrocket to nearly 14 or 15 million Americans by 2050.

Brent Forester, MD, MSc, shares more about the neurocognitive epidemic of our time: dementia. As the baby boomer population ages, we are starting to see a rapid escalation of individuals with neurocognitive disorders both in America and worldwide.

Dr Forester is the chief of the Division of Geriatric Psychiatry at McLean Hospital and medical director for Dementia Care and Behavioral & Mental Health Population Health Management at Mass General Brigham. He is also associate professor of psychiatry at Harvard Medical School.

Related Videos
dementia
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
What is the efficacy of ECT for the treatment of dementia?

Electroconvulsive Therapy in Individuals with Behavioral and Psychological Symptoms of Dementia

April 22nd 2024
Article
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review

April 3rd 2024
Article
The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From the Pages of Psychiatric Times: March 2024

March 30th 2024
Article
From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

The Week in Review: March 11-15

March 16th 2024
Article
“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

Mild Cognitive Impairment and Serotonin System Degeneration

March 14th 2024
Article
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

February 20th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.